ÝËÅÊÒÐÎÔÈÇÈÎËÎÃÈ×ÅÑÊÈÅ È ÀÍÒÈÀÐÈÒÌÈ×ÅÑÊÈÅ ÝÔÔÅÊÒÛ ÍÎÂÎÃÎ ÎÒÅ×ÅÑÒÂÅÍÍÎÃÎ ÀÍÒÈÀÐÈÒÌÈ×ÅÑÊÎÃÎ ÏÐÅÏÀÐÀÒÀ III ÊËÀÑÑÀ ÍÈÔÅÐÈÄÈËÀ. ÑÎÎÁÙÅÍÈÅ I: ÝËÅÊÒÐÎÔÈÇÈÎËÎÃÈ×ÅÑÊÈÅ ÝÔÔÅÊÒÛ ÍÈÔÅÐÈÄÈËÀ Ó ÁÎËÜÍÛÕ ÏÀÐÎÊÑÈÇÌÀËÜÍÛÌÈ ÍÀÄÆÅËÓÄÎ×ÊÎÂÛÌÈ ÒÀÕÈÊÀÐÄÈßÌÈ

Àííîòàöèÿ
Ñ öåëüþ äåòàëüíîãî èçó÷åíèÿ ýëåêòðîôèçèîëîãè÷åñêèõ ýôôåêòîâ íîâîãî îòå÷åñòâåííîãî ïðåïàðàòà III êëàññà íèôåðèäèëà â ðàìêàõ ôàçû II êëèíè÷åñêîãî èñïûòàíèÿ îáñëåäîâàíî 25 ïàöèåíòîâ (18 ìóæ÷èí) â âîçðàñòå îò 19 äî 73 ëåò ñ äîêóìåíòèðîâàííûìè ïàðîêñèçìàìè íàäæåëóäî÷êîâûõ òàõèêàðäèé.

Annotation
To study in detail electrophysiological properties of Niferidil, a novel III-class antiarrhythmic manufactured in Russia, 25 patients including 18 men aged 19 73 years with documented paroxysms of supraventricular tachycardia were examined during a Phase II clinical trial.


Àâòîð
Ìèðîíîâ, Í. Þ., Ãîëèöûí, Ñ. Ï., Ñîêîëîâ, Ñ. Ô., Ìàéêîâ, Å. Á., Øëåâêîâ, Í. Á., Þðè÷åâà, Þ. À., Ìàðååâ, Þ. Â., Ðîçåíøòðàóõ, Ë. Â., ×àçîâ, Å. È.

Íîìåðà è ðóáðèêè
ÂÀ-¹70 îò 01/12/2012, ñòð. 5 /.. Îðèãèíàëüíûå èññëåäîâàíèÿ